Malaysia’s pharmaceutical supply chain remains resilient, with the majority of monitored medicines holding sufficient inventory to last more than three months.
The Ministry of Health reported that over 60% of tracked drugs have stock levels exceeding 90 days, a metric that underscores the stability of the domestic healthcare infrastructure.
0% in May, while Moody's Ratings affirmed the country's long-term issuer ratings at A3 with a stable outlook.
The data also highlights a structural shift in the country's pharmaceutical landscape, as reliance on imported medicines shows signs of declining.
This reduction in import dependence suggests a gradual strengthening of local manufacturing capabilities or more diversified sourcing strategies, which could insulate the market from external supply shocks.
The stability in medicine supply comes against a backdrop of broader economic steadiness in Malaysia.
Recent data indicated that the unemployment rate held steady at 3.0% in May, while Moody's Ratings affirmed the country's long-term issuer ratings at A3 with a stable outlook.